Journal article

Efficacy of dexamethasone versus bevacizumab on regression of hard exudates in diabetic maculopathy: data from the BEVORDEX randomised clinical trial

Hemal Mehta, Samantha Fraser-Bell, Aaron Yeung, Anna Campain, Lyndell L Lim, Godfrey J Quin, Ian L McAllister, Pearse A Keane, Mark C Gillies



OBJECTIVE: To report the effect of bevacizumab versus dexamethasone on hard exudates (HEX) in diabetic macular oedema (DME). DESIGN: Post hoc analysis of 24-month data from the Randomised clinical trial of BEVacizumab OR DEXamethasone for diabetic macular oedema (BEVORDEX) phase 2 multicentre randomised clinical trial. Eyes with centre-involving DME resistant to or unlikely to benefit from macular laser therapy were included. Eyes were randomly assigned to bevacizumab every 4 weeks or Ozurdex dexamethasone implant (DEX) every 16 weeks, both as required. The 68 eyes from 48 patients that completed 24-month follow-up were analysed. Two masked graders assessed extent and location of HEX on base..

View full abstract


Awarded by National Institute for Health Research

Funding Acknowledgements

This study was funded by a project grant from the National Health and Medical Research Council (NHMRC), which was supplemented by an unrestricted educational grant from Allergan Pharmaceuticals. MCG is a Sydney Medical School Foundation Fellow and is supported by an NHMRC Clinical Fellowship. PAK has received a proportion of his funding from the Department of Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views expressed in the publication are those of the authors and not necessarily those of the NHMRC or Department of Health. The funding bodies had no influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit for publication.